PHVS Stock Analysis: Pharvaris BV | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.372m USD | 12M Return: 92.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 12.2M
Qual. Beats: -1
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Pharvaris N.V. is a late-stage biopharmaceutical company developing therapies for rare diseases, with a primary focus on angioedema and other bradykinin-mediated conditions. Its lead candidate, deucrictibant, is a small molecule bradykinin B2-receptor antagonist being evaluated in Phase 3 trials for the treatment and prophylaxis of hereditary angioedema (HAE) attacks, as well as for acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH). The company is advancing both an extended-release tablet and an immediate-release capsule formulation of the drug.
Founded in 2015 and headquartered in Zug, Switzerland, Pharvaris operates in the biotechnology sub-sector of health care, where companies typically derive long-term value from clinical pipeline progression and eventual regulatory approvals. As a rare disease-focused biopharma, the company is positioned in a segment that often benefits from orphan drug regulatory pathways, which can provide extended market exclusivity upon approval.
- Deucrictibant Phase 3 HAE prophylaxis data readout approaches
- FDA approval pathway for deucrictibant HAE therapy advances
- Competition intensifies from Takeda, BioCryst, Ionis in HAE market
- Cash burn and potential equity raise risk persist pre-commercial
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.57 > 0.02 and ΔFCF/TA -2.62 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.57 > 3% & CFO -148.2m > Net Income -169.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 11.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (65.3m) vs 12m ago 19.78% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.90 (Total Current Assets 257.7m - Total Current Liabilities 22.9m) / Total Assets 259.8m |
| B: -2.38 (Retained Earnings -619.5m / Total Assets 259.8m) |
| C: -0.68 (EBIT TTM -172.6m / Avg Total Assets 253.9m) |
| D: 10.08 (Book Value of Equity 236.3m / Total Liabilities 23.5m) |
| Altman-Z'' = 4.16 = AA |
As of July 08, 2026, the stock is trading at USD 34.59 with a total of 972,678 shares traded. Over the past week, the price has changed by -0.35%, over one month by +9.50%, over three months by +24.25% and over the past year by +92.17%.
Current recommended Stop Loss: 32.60 (which is 5.8% or 1.3 ATR below the current price).
Pharvaris BV has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy PHVS.
- StrongBuy: 6
- Buy: 2
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 46.3 | 33.8% |
Market Cap EUR = 2.08b (2.37b USD * 0.8764 USD.EUR)
P/B = 8.7981
Revenue TTM = 0.0 EUR
EBIT TTM = -172.6m EUR
EBITDA TTM = -172.2m EUR
Long Term Debt = 533k EUR (estimated: total debt 739k - short term 206k)
Short Term Debt = 206k EUR (from shortTermDebt, last quarter)
Debt = 739k EUR (from shortLongTermDebtTotal, last quarter) (leases 739k already included)
Net Debt = -246.2m EUR (calculated: Debt 739k - CCE 247.0m)
Enterprise Value = 1.83b EUR (2.08b + Debt 739k - CCE 247.0m)
Interest Coverage Ratio = unknown (Ebit TTM -172.6m / Interest Expense TTM 0.0)
EV/FCF = -12.37x (Enterprise Value 1.83b / FCF TTM -148.2m)
FCF Yield = -8.09% (FCF TTM -148.2m / Enterprise Value 1.83b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 7.06 (Enterprise Value 1.83b / Total Assets 259.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 739k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -136.4m (EBIT -172.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.24 (Total Current Assets 257.7m / Total Current Liabilities 22.9m)
Debt / Equity = 0.00 (Debt 739k / totalStockholderEquity, last quarter 236.3m)
Debt / EBITDA = 1.43 (negative EBITDA) (Net Debt -246.2m / EBITDA -172.2m)
Debt / FCF = 1.66 (negative FCF - burning cash) (Net Debt -246.2m / FCF TTM -148.2m)
Total Stockholder Equity = 251.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -66.64% (Net Income -169.2m / Total Assets 259.8m)
RoE = -67.40% (Net Income TTM -169.2m / Total Stockholder Equity 251.0m)
RoCE = -68.62% (EBIT -172.6m / Capital Employed (Equity 251.0m + L.T.Debt 533k))
RoIC = -57.53% (negative operating profit) (NOPAT -136.4m / Invested Capital 237.1m)
WACC = 7.61% (E(2.08b)/V(2.08b) * Re(7.61%) + D(739k)/V(2.08b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 7.61% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 10.38%
[DCF] Fair Price = unknown (Cash Flow -148.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.25 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.65 | Chg30d=+1.01% | Revisions=+50% | Analysts=11
EPS next Quarter (2026-09-30): EPS=-0.66 | Chg30d=+0.74% | Revisions=+50% | Analysts=11
EPS current Year (2026-12-31): EPS=-2.59 | Chg30d=+1.00% | Revisions=+58% | GrowthEPS=+12.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.32 | Chg30d=+1.31% | Revisions=+0% | GrowthEPS=+10.4% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +50% (up=24, down=7)